8 results about "Urothelium" patented technology

The present application relates to the field of medical devices and discloses a ureteral stent and a preparation method thereof. The ureteral stent comprises a stent body and a nanofiber membrane. The stent body is woven into a 90-140ppi tube by spinning component A and component B in a mass ratio of 4:(1-2). The spun yarn obtained by component B is melted by heating and then combined with the spun yarn obtained by component A. The stent body is obtained after cooling. The nanofiber membrane components include polyethylene glycol and polyglycolide, as well as fucoidan-modified chitosan. A lubricant is sprayed on one side of the nanofiber membrane away from the stent body, and the membrane is wound around the outer surface of the stent body by electrostatic adsorption. The ureteral stent increases the stability and stiffness of the tube wall, improves the mechanical strength and durability, and the material is biocompatible and biodegradable, and can reduce irritation and damage to the urothelium, and prevent urothelial tissue ingrowth and adhesion.

The invention provides an amnion-integrated tubular porous scaffold as well as a preparation method and application thereof. The preparation method comprises the following steps: (S10) extracting silk fibroin from silkworm cocoons by adopting a lithium bromide dissolution method; (S20) adopting detergent treatment and enzyme digestion to prepare the decellularized amnion; (S30) mixing silk fibroin and pigskin gelatin to prepare a silk fibroin / gelatin solution; and (S40) integrating the decellularized amniotic membrane with the silk fibroin / gelatin stent to obtain the tubular porous stent integrated with the amniotic membrane, so that the tubular porous stent can increase urinary tract epithelization and inhibit fibrosis, is suitable for being applied to ureter scar-free repair treatment, ureter defect repair treatment or ureter reconstruction, and provides a new treatment strategy for ureter defect repair treatment.

The present invention provides a method for treating and / or ameliorating a disorder of the lower urinary tract, comprising administering a composition comprising a glucagon like peptide 2 (GLP-2) receptor agonist to a patient in need thereof in an amount sufficient to treat and / or ameliorate the disorder of the lower urinary tract.

The invention relates to the technical field of tumor molecular diagnosis, and particularly discloses a primary prostate urothelium carcinoma (PUCP) typing method based on MTRNR2L12 expression characteristics and application of the primary prostate urothelium carcinoma (PUCP) typing method. The specific expression characteristics of the MTRNR2L12 gene in the primary prostatic urothelial carcinoma are systematically revealed from a plurality of links such as single cell separation and sequencing, data preprocessing and clustering, subtype division and CNV analysis, function enrichment analysis, public data integration and trajectory reconstruction, differential expression and clinical sample verification; therefore, the MTRNR2L12 can be used as a molecular marker for diagnosing the PUCP, and the accuracy of clinical early recognition is improved. The invention can be applied to molecular typing and auxiliary diagnosis of suspected prostate tumor samples, and has important clinical transformation potential.

The invention relates to a methylation marker kit for urinary tract epithelial cancer, and further relates to a reagent capable of detecting the methylation state of a DNA area where a target gene in a sample is located and application of the reagent in preparation of the urinary tract epithelial cancer detection kit, and the target gene comprises HOXA9 and / or any one or more genes selected from the group consisting of VIM, SIM2, ZIC4, ZNF154, KCNMA1, FOXF2, TRPS1, RAB37, SEPT9, LHX8, NKX6-2, ZNF571-AS1, NKX1-1, MARCH11, PENK, TBX15, NKX2-8, NRN1, BCL11B, ALX1, KCNQ1DN, LRRC9, BNC1, IRX4 The invention also provides a method for detecting urothelial carcinoma.

The invention provides a TGF-beta1 signal channel inhibitor and a method and application thereof for regulating and controlling Fmod expression, the TGF-beta1 signal channel inhibitor is decellularized amnion integrated silk fibroin / gelatin, TGF-beta1 signal transduction is antagonized by up-regulating Fmod expression, the TGF-beta1 signal channel inhibitor is suitable for being applied to a ureter porous stent, urinary tract epithelization can be increased, fibrosis can be inhibited, and the TGF-beta1 signal channel inhibitor can be used for preparing a ureter stent. Therefore, the method is used for ureteral scar-free repair treatment, ureteral defect repair treatment or ureteral reconstruction, and is of great significance to the development of ureteral tissue engineering.

The present invention provides methods, compositions, and kits for treating bladder disorders or conditions, in which botulinum toxin is topically administered to the mucosal inner lining or urothelium of the bladder, of a subject in need thereof, for transmucosal delivery across the urothelium to surrounding bladder wall musculature and / or neuronal tissue. Rather than requiring injection, the toxin instead may be administered by instillation in solution via the urethra. In particular, the botulinum toxin is administered in conjunction with a positively charged or lipophilic carrier comprising a positively charged polymeric backbone or a hydrophobic backbone with covalently attached groups that enhance transmucosal transport across the urothelium and may also stabilize the botulinum toxin in aqueous formulations.

The present invention provides a method of treating a patient suffering from bladder pain syndrome, said method comprising administering a solution containing a clostridial neurotoxin into the bladder of the patient; increasing the volume of solution comprising the clostridial neurotoxin present within the bladder, thereby applying a mechanical force against the inner surface of the urothelial layer; and maintaining said volume of solution comprising the clostridial neurotoxin present within the bladder at a volume that does not give rise to patient micturition and for a duration of at least 30 minutes, thereby allowing the clostridial neurotoxin to diffuse across the urothelial layer and into the lamina propria, where the clostridial neurotoxin binds to primary sensory afferent nerve fibres, suppresses secretion of neurotransmitters therefrom, and alleviates bladder pain.